辛伐他汀治疗慢性阻塞性肺疾病效果及对患者BNP影响.docVIP

辛伐他汀治疗慢性阻塞性肺疾病效果及对患者BNP影响 　　[摘要]目的 研究辛伐他汀治疗慢性阻塞性肺疾病的效果及其对患者血浆脑利钠肽的影响。方法 选取2015年10月～2016年4月我院呼吸内科就诊的180例慢性阻塞性肺疾病患者，随机分为对照组和治疗组各90例；两组患者接受常规治疗，治疗组加用辛伐他汀；治??8个月后，对比治疗前后患者肺功能相关指标、呼吸困难评分指标、血浆BNP含量。结果 治疗8个月后患者FEV1%、FEV1/FVC均较治疗前明显好转（P0.05）；治疗组呼吸困难问卷（mMRC）评估等级较治疗前显著降低，治疗组基础呼吸困难指数（BDI）评分同对照组比较差异有统计学意义（P0.05）；治疗组患者BNP水平较对照组显著降低（P0.05）。结论 辛伐他汀结合常规治疗慢性阻塞性肺疾病能改善患者肺功能及呼吸困难评分，能使患者BNP降低，值得临床推广。 　　[关键词]辛伐他汀；慢性阻塞性肺疾病；临床效果；血浆脑利钠肽 　　[中图分类号] R563.9 [文献标识码] A [文章编号] 1674-4721（2017）06（a）-0045-03 　　[Abstract]Objective To research the curative effect of Simvastatin treatment for chronic obstructive pulmonary disease and its effects on patients with plasma brain natriuretic peptide.Methods 180 cases of chronic obstructive pulmonary disease patients were selected as the research object，in the department of respiratory medicine，from October 2015 to April 2016.They were randomly divided into control group and treatment group，90 cases in each group.Two groups of patients were treated with routine，Simvastatin treatment group patients were used；eight months after treatment，two groups of patients were compared before and after treatment in patients with lung function index，dyspnea score index，plasma BNP levels.Results After 8 months of treatment，two groups of patients with FEV1% and FEV1/FVC levels were significantly better than before treatment（P0.05）；treatment group patients were found to breathing difficulties questionnaire（mMRC） assessment level was significantly reduced，and the patients in treatment group were found based dyspnea index （BDI） score compared with the control group with significant difference（P0.05）；treatment group patients were found the BNP level was significantly reduced（P0.05）.Conclusion Simvastatin combined with routine treatment of chronic obstructive pulmonary disease patients to improve patients′ lung function and respiratory difficulty score，can reduce patients BNP，worth clinical promotion. 　　[Key words] Simvastatin； Chronic obstructive pulmonary disease； Clinical